Skip to main
CNTA

CNTA Stock Forecast & Price Target

CNTA Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 30%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Centessa Pharmaceuticals PLC is advancing its Orexin Receptor 2 Agonist Program and LockBody Technology Platform, focusing on small molecule therapeutics aimed at addressing various neuroscience diseases related to the orexin pathway. With preliminary data indicating best-in-class efficacy for ORX750 and expectations for additional supportive data by 1Q26, the company has a projected sales potential of approximately $3.6 billion, highlighting significant upside for investors. Management's comments on the drug's safety profile and the potential for optimized dosing strategies further enhance the positive outlook for Centessa Pharmaceuticals and its pipeline.

Bears say

The outlook for Centessa Pharmaceuticals's stock is negatively influenced by multiple fundamental factors, including regulatory uncertainties regarding acquisition completions and potential setbacks affecting key drug candidates, cleminorexton and ORX142. Additionally, high non-responder rates and late-day waning efficacy observed in clinical trials raise concerns about the overall viability of the orexin receptor 2 agonist class, indicating possible fundamental limitations in both dose selection and administration compliance. Furthermore, the complexity introduced by variability in Phase 2 trial results, coupled with increasing competitive pressures in the market, further compounds the challenges facing Centessa’s development pipeline, potentially impacting future financial performance.

CNTA has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 30% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Centessa Pharmaceuticals PLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Centessa Pharmaceuticals PLC (CNTA) Forecast

Analysts have given CNTA a Buy based on their latest research and market trends.

According to 10 analysts, CNTA has a Buy consensus rating as of Apr 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Centessa Pharmaceuticals PLC (CNTA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.